8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2005 (June 1, 2005)

GTx, Inc.

(Exact name of registrant as specified in its charter)

Delaware	005-79588	62-1715807
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)

3 N. Dunlap Street
3^rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)

(Former name or former address, if changed since last report)

TABLE OF CONTENTS

	ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
	ITEM 9.01 Financial Statements and Exhibits
SIGNATURE
EX-99.1 PRESS RELEASE 06/01/05

ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On June 1, 2005, GTx, Inc. announced the appointment of Dr. Robert Karr to serve as a Class I member of its Board of Directors. Dr. Karr will serve on the Nominating and Corporate Governance Committee. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit
Number		Description
	99.1	Press Release issued by GTx, Inc. dated June 1, 2005

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GTx, Inc.
Date: June 2, 2005	By:	/s/ Henry P. Doggrell
		Name:	Henry P. Doggrell
		Title:	Vice President, General Counsel/Secretary

EX-99.1

                                                                    Exhibit 99.1



              GTX INC. ANNOUNCES THE APPOINTMENT OF DR. ROBERT KARR
                            TO ITS BOARD OF DIRECTORS



MEMPHIS, Tenn., June 1, 2005--GTx, Inc., (Nasdaq: GTXI) a biopharmaceutical
company dedicated to the discovery, development and commercialization of
therapeutics primarily related to the treatment of serious men's health
conditions, today announced the appointment of Robert Karr, M.D. to its Board of
Directors. Dr. Karr will become a member of the Board's Nominating and Corporate
Governance Committee.

"We are pleased to welcome Dr. Karr to our board of directors," said Mitchell
Steiner, M.D., CEO of GTx. "Dr. Karr brings to GTx both medical and senior
executive pharmaceutical industry experience in research and development."

As a senior executive for Global Research & Development for Pfizer, Inc., Dr.
Karr served as Senior Vice President, Strategic Management, responsible for
leading Pfizer's research and development strategy group. Prior to its merger
with Pfizer, Dr. Karr served as Vice President, Research & Development Strategy
for Warner-Lambert Company.

Dr. Karr received his B.S. (with honors) from Southwestern University in 1971
and his M.D. from the University of Texas Medical Branch in 1975. Dr. Karr
completed his internship and residency in internal medicine at Washington
University School of Medicine and served as a faculty member at both the
University of Iowa College of Medicine and Washington University School of
Medicine.

ABOUT GTX

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics primarily related to the treatment of serious
men's health conditions and oncology. GTx's drug discovery and development
programs are focused on small molecules that selectively modulate the effects of
estrogens and androgens, two essential classes of hormones.

GTx has four clinical programs. In two of its clinical programs, the company is
developing ACAPODENE(R) (toremifene citrate) for two separate indications in
men: (1) a pivotal Phase III clinical trial for the prevention of prostate
cancer in high risk men and (2) a pivotal Phase III clinical trial for the
treatment of serious side effects of androgen deprivation therapy for advanced
prostate cancer. In its third clinical program, GTx and its partner, Ortho
Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing
andarine, a SARM, for cancer related muscle wasting, including cancer cachexia.
In its fourth clinical program, GTx is developing its second SARM, ostarine, for
frailty and andropause, conditions which are associated with the loss of muscle
mass and bone. GTx also has a marketed product, FARESTON(R) (toremifene citrate
60mg) tablets, utilizing the same active pharmaceutical ingredient as
ACAPODENE(R), for the treatment of metastatic breast cancer. In addition, GTx
has an extensive preclinical pipeline generated from its own discovery program
which includes the specific product candidates, prostarine, a SARM for benign
prostatic hyperplasia (BPH), and andromustine, an anticancer product candidate,
for hormone refractory prostate cancer.


CONTACT:  Marc S. Hanover
          President and Chief Operating Officer
          GTx, Inc.
          901-507-6915
       /Web site: http://www.gtxinc.com/